The Immune-Buffer COVID-19 Exit Strategy that Protects the Elderly

Author:

Rom-Kedar VeredORCID,Yaniv Omer,Malka Roy,Shapiro Ehud

Abstract

AbstractSeptember 12, 2020COVID-19 is a viral respiratory illness, caused by the SARS-CoV-2 virus with frequent symptoms of fever and shortness of breath [1]. COVID-19 has a high mortality rate among elders. The virus has spread world-wide, leading to shut-down of many countries around the globe with the aim of stopping the spread of the disease. To date, there are uncertainties regarding the main factors in the disease spread, so sever social distancing measures and broad testing are required in order to protect the population at risk. With the increasing spread of the virus, there is growing fraction of the general population that may be immune to COVID-19, following infection. This immunised cohort can be uncovered via large-scale screening for the SARS-CoV-2 (Corona) virus and/or its antibodies. We propose that this immune cohort be deployed as a buffer between the general population and the population most at risk from the disease. Here we show that under a broad range of realistic scenarios deploying such an immunized buffer between the general population and the population at risk may lead to a dramatic reduction in the number of deaths from the disease. This provides an impetus for: screening for the SARS-CoV-2 virus and/or its antibodies on the largest scale possible, and organizing at the family, community, national and international levels to protect vulnerable populations by deploying immunized buffers between them and the general population wherever possible.Declarations of interestnone

Publisher

Cold Spring Harbor Laboratory

Reference16 articles.

1. Li, Q. et al. Early transmission dynamics in wuhan, china, of novel coronavirus infected pneumonia. New England Journal of Medicine (2020).

2. Onder, G. , Rezza, G. & Brusaferro, S. Case-fatality rate and characteristics of patients dying in relation to covid-19 in italy. Jama (2020).

3. WHO Organization , Report of the WHO-china joint mission on coronavirus disease 2019 (covid-19) (2020).

4. Richardson, S. et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with covid-19 in the new york city area. JAMA (2020).

5. Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with covid-19 in wuhan, china: a retrospective cohort study. The Lancet (2020).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3